Cleo Diagnostics Ltd
COV.ASXHealth Care
Medical diagnostics/devices development and commercialisation
Market Data
$0.550
-0.1%$80.1M
-100000.0x
$-0.030
0.00%
-0.1%
Latest Earnings
Appendix 4D and Half Yearly Accounts
25 February 2026
Cleo Diagnostics reported a half-year loss of $1.98M, marginally higher than the prior period, while revenue fell 53% to $89k primarily due to lower interest income. The company raised $5M in funding and advanced key clinical trials for its ovarian cancer diagnostic test, with 18 trial sites active and on track to hit 500 patient recruitment target in Q1 CY2026. Key points: Raised $5M in December, ending with $9.4M cash on hand for continued operations; Clinical trials progressing well with 18 active trial sites and on track for 500 patient recruitment target in Q1 CY2026; Received positive feedback from second FDA pre-submission meeting and completed Stage 1 of Medical Device Single Audit Program
Recent Announcements
Appendix 4D and Half Yearly Accounts
Cleo Diagnostics reported a half-year loss of $1.98M, marginally higher than the prior period, while revenue fell 53% to $89k primarily due to lower interest income. The company raised $5M in funding and advanced key clinical trials for its ovarian cancer diagnostic test, with 18 trial sites active and on track to hit 500 patient recruitment target in Q1 CY2026. Key points: Raised $5M in December, ending with $9.4M cash on hand for continued operations; Clinical trials progressing well with 18 active trial sites and on track for 500 patient recruitment target in Q1 CY2026; Received positive feedback from second FDA pre-submission meeting and completed Stage 1 of Medical Device Single Audit Program
Get real-time alerts for COV
Receive AI-powered earnings summaries and instant notifications when Cleo Diagnostics Ltd releases results.
Register Free